Efficacy of Talquetamab Plus Teclistamab in Patients with Extramedullary Myeloma By Ogkologos - December 10, 2025 265 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the phase II cohort of the RedirecTT-1 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Tarlatamab Transdermal Oestradiol Patches Non-inferior to LHRH Agonists Regarding Metastasis-Free Survival in Patients with Locally Advanced Prostate Cancer EMA Recommends Extension of Indications for Selpercatinib MOST POPULAR PRO Data Can Help When Deciding Between Neoadjuvant FOLFOX or Fluorouracil-Based... July 10, 2023 Nivolumab Achieves High ORR and Durable PFS in Patients with dMMR/MSI-H... May 3, 2024 EMA Recommends Granting a Conditional Marketing Authorisation for Nogapendekin alfa Inbakicept January 15, 2026 EMA Adopts a Positive Opinion for Biosimilar Denosumab May 28, 2025 Load more HOT NEWS Spurred by Survivors, Researchers Are Revisiting Cancer Drug Doses High Tumour Mutation Burden Fails to Predict Response to Immune Checkpoint... After Misdiagnosis, Mom Found Out She Had Terminal Breast Cancer Shortly... Scanxiety
